Crossmark

Affinity war: PSAT1 outcompetes the rest

Crossref DOI link: https://doi.org/10.1038/s42255-024-01096-7

Published Online: 2024-08-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Possemato, Richard http://orcid.org/0000-0002-2401-0030
License Information

Text and Data Mining valid from 2024-08-27

Version of Record valid from 2024-08-27
More Information

Article History

First Online: 27 August 2024

Competing interests

: R.P. holds equity in Raze Therapeutics, which holds patents on PHGDH inhibitors.